What is Altimmune's R&D?

Altimmune (ALT) reported R&D of $16.19M in Q1 2026.

How has Altimmune's R&D changed year-over-year?

Altimmune's R&D increased by 2.3% year-over-year, from $15.83M to $16.19M.

What is the long-term trend for Altimmune's R&D?

Over 4 years (2021 to 2025), Altimmune's R&D has grown at a -2.8% compound annual growth rate (CAGR), from $74.54M to $66.43M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Altimmune ALT R&D

R&D at other companies

Eli LillyLLY

$3.51B+28.4%

Merck & Co.MRK

$12.59B+248%

Madrigal Pharmaceuticals, Inc.MDGL

$108.69M+146%

Viking TherapeuticsVKTX

$150.15M+263%

Wave Life SciencesWVE

$47.44M+16.8%

Delcath SystemsDCTH

$9.82M+96.2%

Other financials

Income statement

See full

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's R&D?: Altimmune (ALT) reported R&D of $16.19M in Q1 2026.
How has Altimmune's R&D changed year-over-year?: Altimmune's R&D increased by 2.3% year-over-year, from $15.83M to $16.19M.
What is the long-term trend for Altimmune's R&D?: Over 4 years (2021 to 2025), Altimmune's R&D has grown at a -2.8% compound annual growth rate (CAGR), from $74.54M to $66.43M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.